PMID: 184367Oct 1, 1976

High density lipoproteinuria in nephrotic syndrome

Metabolism: Clinical and Experimental
S G de MendozaR F Lutmer


Intravenous administration of the aminonucleoside of puromycin produces the nephrotic syndrome (proteinuria, hypercholesterolemia, hypoproteinemia and edema) in rats. This model is very similar to human nephrotic syndrome caused by various disease states. The current study was designed to assess the nature of urinary lipoproteins in the urine of nephrotic rats, including studies related to the urinary loss of the "activator" apolipoproteins for the lipoprotein lipase-triglyceride interaction. Sprague-Dawley rats were given a single intravenous injection (10 mg/100 g) of puromycin aminonucleoside. Plasma and urine were collected before and 7, 18, 29, 36, and 53 days after injection of puromycin. Urine was fractionated in the preparative ultracentrifuge into density (d) fractions less than 1.006 (very low-density lipoproteins), d = 1.006-1.063 (low-density lipoproteins), and d = 1.063-1.210 (high-density lipoproteins--HDL). The cholesterol, triglyceride, phospholipid, and protein content of these fractions was analyzed. Lipoprotein electrophoresis was performed in agarose agar. Urine from normal and nephrotic rats was added to an in vitro system containing lipoprotein lipase and triglyceride. The free fatty acids (FFA) liberated ...Continue Reading


Apr 1, 1988·European Journal of Pediatrics·U QuerfeldK Schärer
Oct 1, 1993·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·M A ThabetJ C Chan
Jan 1, 1988·International Urology and Nephrology·K SakuK Arakawa
May 16, 1979·Clinica Chimica Acta; International Journal of Clinical Chemistry·M Lopes-VirellaJ A Colwell
Dec 9, 1981·Clinica Chimica Acta; International Journal of Clinical Chemistry·T Ohta, I Matsuda
Dec 24, 1981·Clinica Chimica Acta; International Journal of Clinical Chemistry·M K ChanJ F Moorhead
Sep 30, 1987·Clinica Chimica Acta; International Journal of Clinical Chemistry·D JüngstP Weisweiler
Jun 15, 2005·Journal of Pharmacological and Toxicological Methods·Susan G Emeigh Hart
Nov 10, 1979·Lancet·E N Wardle
Nov 10, 1979·Lancet·G Proud, J Chamberlain
Dec 1, 1990·Baillière's Clinical Endocrinology and Metabolism·C D Short, P N Durrington
Apr 1, 1996·Australian and New Zealand Journal of Medicine·M GraceyC Chin
Dec 15, 2011·Journal of Atherosclerosis and Thrombosis·Tetsuo ShojiCommittee of Renal and Peripheral Arteries, Japan Atherosclerosis Society
May 1, 1984·Metabolism: Clinical and Experimental·N MorisakiA Kumagai
May 1, 1984·Metabolism: Clinical and Experimental·K SakuM L Kashyap
Oct 1, 1984·Metabolism: Clinical and Experimental·K MimuraH Nomoto
May 1, 1988·Kidney International·J R Diamond, M J Karnovsky
Jun 1, 1988·Kidney International·G L Vega, S M Grundy
Nov 1, 1987·Kidney International·J R Diamond, M J Karnovsky
Nov 1, 1983·Kidney International·S KlahrM L Purkerson
Jan 1, 1982·Critical Reviews in Clinical Laboratory Sciences·D G Cramp
Jan 1, 1989·Diabetic Medicine : a Journal of the British Diabetic Association·G F WattsK M Shaw
Dec 1, 1984·Australian and New Zealand Journal of Medicine·M K ChanJ F Moorhead


Aug 18, 1975·Clinica Chimica Acta; International Journal of Clinical Chemistry·R Ekman, P Nilsson-Ehle
Sep 19, 1974·Biochimica Et Biophysica Acta·S Diamant, E Shafrir
Apr 1, 1974·Proceedings of the National Academy of Sciences of the United States of America·G Assmann, H B Brewer
Aug 1, 1967·The Biochemical Journal·V P SkipskiF M Archibald
Sep 1, 1955·The Journal of Clinical Investigation·R J HAVELJ H BRAGDON
Jul 1, 1955·Proceedings of the Society for Experimental Biology and Medicine·S FRENKJ METCOFF
Jan 1, 1959·The Journal of Experimental Medicine·R L VERNIERR A GOOD

Related Concepts

Nephrotic Syndrome
Electrophoresis, Agar Gel
Alpha-1 Lipoprotein

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.